Overview

Jake focuses on healthcare law, and his work encompasses a range of regulatory, transactional and corporate matters. He counsels clients with regard to the legal aspects of day-to-day operations, including general corporate matters; anti-kickback and Stark issues; self-referral, corporate practice of medicine and fee-splitting prohibitions; compliance; state regulatory and licensure matters; and HIPAA and health information privacy.

Jake regularly represents a variety of dialysis and nephrology providers, vascular access center operators and owners, hospitals, physician group practices, infusion therapy owners and operators, behavior health providers, skilled nursing facilities, healthcare information technology companies and other healthcare providers in structuring mergers and acquisitions, joint ventures, accountable care and capitated care arrangements, syndications and divestitures.

Jake was recognized by his peers in the 2025 edition of Best Lawyers: Ones to Watch® in America for his exceptional work in Health Care Law.

Earlier in Jake’s career, he practiced as a litigator for Chicago-based law firms. He also has served as staff assistant to U.S. Senator Tom Harkin and to the Senate Committee on Health, Education, Labor and Pensions.

Featured endorsements

Credentials

Education

DePaul University College of Law, 2009, J.D., cum laude
  • Order of the Barristers
Loyola University Chicago School of Law, 2015, LL.M., Health Law and Policy
Iowa State University, B.S. in Finance, with Distinction
  • Dean’s List

Bar & Court Admissions

U.S. District Court for the Southern District of Indiana
U.S. District Court for the Northern District of Illinois
Illinois

More

  • Listed, The Best Lawyers in America®: Ones to Watch, Health Care Law, 2024-2025

Related News & Insights

Client Alerts & Insights 5.21.26

The LEAD Model—Kidney Care’s Value-Based Care Journey LEADs Here

For more than a decade, nephrology practices have participated in Innovation Center kidney‑focused models—beginning with ESRD Seamless Care Organizations (“ESCOs”) under the Comprehensive ESRD Care (“CEC”) Model (2015–2021), followed by today’s Kidney Care Choices (“KCC”) Model (2022–2027). With KCC scheduled to end in December 2027, kidney care providers are approaching a critical transition point. The Long‑term Enhanced ACO Design (“LEAD”) Model, for which CMS released the Request for Applications (“RFA”) on March 31, 2026 (revised April 15, 2026), represents the next phase of CMS’s value‑based care strategy—but it differs fundamentally from the kidney‑specific models that preceded it.